Fuente: Prohibición Partners Lugar: General Report Contents
Jump to any section in the series
















Introduction →
Definitions And Scope →
Executive Summary →
Key Trends →

Market Value →
Legislation and Regulation →
Consumer Attitudes →
Healthcare Providers’ Attitudes →

Spotlight On Health →
Psychedelics – Timeline of Key Developments →
Countries to Watch →
Psychedelic Profiles →

Key Psychedelics Deep Dive →
Other Psychedelics of Note →
Psychedelics as Medicine: Potential Therapies →
Psychedelics and Technology →

Psychedelics Per Country →
Psychedelics and The Law →
Patents and Intellectual Property →
Therapy Practitioners →

Psychedelic Research →
Glossary →


No matches. Try a different keyword.









Key Takeaways



More than 50,000 therapists are expected to be trained to administer psychedelic-assisted therapy (PAT) over the next decade. Organisations including MAPS, COMPASS Pathways, the California Institute of Integral Studies (CIIS), and a growing number of training providers have already begun scaling education programmes to meet anticipated demand.



In current clinical trials, therapists work in co-therapy dyads, and a full psychedelic-assisted treatment protocol can require more than 40 hours of therapist involvement per patient. New delivery models—such as group therapy, shorter-acting compounds, or technology-assisted care—could significantly reduce time requirements and costs, though their effectiveness remains under investigation.



The Role of Therapists in Psychedelic-Assisted Therapy



Therapists and clinicians are the backbone of psychedelic-assisted therapy delivery. The ability to fund, scale, and sustain high-quality training programmes—and to ensure a steady pipeline of trained practitioners—is critical to the broader adoption of psychedelic therapies.



As psychedelic-assisted therapy moves from clinical trials toward regulated healthcare settings, therapist availability will be a key constraint. Both non-profit and for-profit organisations delivering PAT must ensure practitioners are consistently trained, upskilled, supervised, and retained to meet growing patient demand.



PAT training is generally available to qualified mental health professionals who wish to work with clients receiving therapy in conjunction with psychedelic substances. Training pathways range from specialised education in preparation and integration services to full qualification as a psychedelic-assisted therapy practitioner.



Training programmes equip healthcare professionals with skills to support altered states of consciousness, guide integration of psychedelic experiences into daily life, and apply harm-reduction techniques. Many therapists also pursue complementary modalities, such as breathwork, to enhance patient support.



Psychedelic Therapy Training Providers



A mix of non-profit and commercial organisations are currently training psychedelic therapists, with projections suggesting more than 50,000 practitioners will be trained globally over the next ten years.



MAPS has been particularly transparent about its training ambitions. Following anticipated FDA approval of MDMA-assisted psychotherapy for PTSD, MAPS expects to hold data exclusivity in the United States from 2023 to 2029, with longer exclusivity periods in Europe. During this window, MAPS aims to train approximately 24,000 therapists.



MAPS’ training programme includes around 100 hours of online coursework, followed by supervised clinical practice and structured feedback during therapists’ first PTSD cases. The cost of the training is approximately US$5,000 and does not include the optional opportunity for trainees to undergo MDMA-assisted therapy themselves.



Capacity Constraints and the Need to Scale



In current clinical trials, each patient typically undergoes around 42 hours of therapy delivered by a male-female co-therapy team. Scaling psychedelic-assisted therapy will therefore be intrinsically linked to expanding the therapist workforce.



Potential strategies to improve scalability include reducing in-person therapy time, introducing group therapy models, and integrating technology into preparation and integration phases. While these approaches may improve access and reduce costs, their clinical efficacy must be validated through further research.



While MAPS training is mandatory for therapists wishing to deliver MDMA-assisted psychotherapy under its protocols, many clinicians seek broader training as general psychedelic therapists. This would allow them to customise treatment approaches, including the potential sequencing of different psychedelic compounds, depending on patient needs.



At present, MAPS is training approximately 310 therapists, with an additional 500 expected to begin training imminently. Physicians who prescribe MDMA will also require training, although their limited role in therapy sessions means this education could be completed in approximately two to four hours.



Emerging Training Programmes and New Models



Beyond MAPS, a growing ecosystem of training providers is emerging. In Canada, ATMA Journey Centres recently completed psychedelic therapy training with 35 professionals, while the non-profit Therapsil launched a beta training programme earlier this year.



In the United States, Fluence provides training in psychedelic integration as well as ketamine-assisted psychotherapy. Access to a ketamine prescriber remains a common bottleneck for independent practitioners seeking to offer ketamine-assisted therapy. Journey Clinical, a US-based start-up, addresses this gap by supplying in-house trained ketamine prescribers and partnering with Fluence on therapist education.



Aspiring psychedelic clinical researchers can also pursue postgraduate training through the California Institute of Integral Studies, which has become a recognised academic hub for psychedelic studies.



Building the Future Psychedelic Therapy Workforce



To meet anticipated demand, collaboration between experienced training providers, academic institutions, and healthcare systems will be essential. Expanding access to psychedelic therapy training will help diversify the therapist workforce and encourage more clinicians to specialise in this emerging field.



As regulatory frameworks evolve and patient demand increases, therapist training capacity will remain one of the most critical factors determining how quickly and equitably psychedelic-assisted therapy can be delivered at scale.








← Previous



Download report ↓



Next →




Prefer the full dataset? Download the complete report (PDF).








Download the full report
Enter your details to access the PDF instantly.

×










The post Therapy Practitioners in Psychedelic-Assisted Therapy – PSYCH: The Psychedelics As Medicine Report 3rd Edition appeared first on Prohibition Partners.